What transparency should look like in medicine access
The documents you should be able to see, and why they protect you.
Reviewed by the Reserve Meds clinical operations team on 18 October 2026. Sources accessed 18 October 2026.
The short answer
Transparency in medicine access means you can see who supplies the medicine and under which licence, how it is traced and kept at the right temperature, which permit allows it into your country, what you are paying for, how long it is expected to take, and who sees your information. You should be able to see each of these in writing.
- Who: the licensed supplier, by name.
- How: the custody and temperature record.
- Allowed by: the permit or approval in your country.
- What and when: a written quote and a written timeline estimate.
Documents you should be able to see
- The supplier's name and licence details.
- The product details: name, strength, batch number and expiry date.
- The temperature record for the journey, once the medicine arrives.
- The permit or approval from your country's regulator or hospital, where one is needed.
- Your written quote, written timeline estimate and refund terms.
- A privacy notice that explains who sees your documents and why.
Why supplier transparency matters
US wholesale drug distributors and third-party logistics providers must be appropriately licensed and must report their licensure to the FDA every year to count as authorized trading partners under that law. The FDA publishes the reports in a searchable database that is updated every business day. A listing is not an FDA licence or approval in itself: the licence is issued by the state, and the database helps you see that a company has reported one.[1]
In the United States, the Drug Supply Chain Security Act sets out an electronic, interoperable way to identify and trace certain prescription medicines at the package level as they move through the supply chain, to keep harmful products out and to find and remove them quickly if they get in.[2]
Why custody transparency matters
WHO's good storage and distribution practices note that medical products face risks at every stage, from purchasing and storage to repackaging, relabelling, transport and distribution, and that many different people and organizations handle them along the way.[3]
The World Health Organization estimates that at least 1 in 10 medicines in low- and middle-income countries is substandard or falsified, and notes that such products are often sold online or in informal markets and include life-saving treatments such as cancer therapies.[4]
Why process transparency matters
Permits, hospital steps and customs can all take time, and some of that time is outside anyone's control. A written timeline estimate that says which steps depend on whom lets you plan, and lets you see when something is stuck.
Rules for unregistered medicines are set by each destination country. In Bahrain, for example, NHRA Circular 41 of 2020 requires a hospital to obtain the authority's permission before it issues a purchase order for a non-registered medicine, and to transport and store the product in containers that follow the manufacturer's recommended conditions.[5]
Why data transparency matters
In the UAE, Federal Decree-Law No. 45 of 2021 on the Protection of Personal Data prohibits processing personal data without the owner's consent, apart from limited cases, gives people the right to ask for corrections and to restrict or stop processing, and sets requirements for sending personal data across borders. It came into force on 2 January 2022.[6]
Saudi Arabia issued its Personal Data Protection Law in September 2021, and the Saudi Data and AI Authority's national data governance platform lets individuals file a complaint about the handling of their personal data.[7]
What Reserve Meds shows you
We name the route for your case, give you a written quote and a written timeline estimate before you commit, and tell you which documents we need and why. You can ask for our wholesale partner's licence details at any time. Our privacy notice explains how we handle your information.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate the route with your treating doctor and hospital, prepare the paperwork the regulator or hospital asks for, and arrange supply once approval is in place. Your doctor prescribes and makes every medical decision. You can ask us for our wholesale partner's licence details, and you get your quote and timeline estimate in writing before you commit.
We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them. Your coordination fee is quoted in writing for your case before you commit. No hidden charges. We give you a written timeline estimate for your case before you commit.
Ask us about a medicine
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
What is the most important document to ask for?
The supplier's name and licence details, because every other check depends on knowing who supplies the medicine.
Should I receive the temperature record?
You should be able to see that the temperature record was reviewed on arrival. WHO's practices expect transport temperature data to be reviewed on receipt.
Do I have rights over my personal data?
In the UAE, the data protection law gives you the right to ask for corrections and to restrict or stop processing. Saudi Arabia has its own Personal Data Protection Law.
Does Reserve Meds share partner licence details?
Yes. Ask us and we will send them.
Sources for these answers: [1, 3, 6, 7]
Sources
All sources were opened and checked on 18 October 2026. Rules and labels change, so the treating hospital or regulator confirms the current position before anything is filed.
- US FDA: Annual Licensure Reporting by Wholesale Drug Distributors and Third-Party Logistics Providers (accessed 18 October 2026)
- US FDA: Drug Supply Chain Security Act (DSCSA) (content current as of 16 October 2025) (accessed 18 October 2026)
- World Health Organization: TRS 1025, Annex 7, Good storage and distribution practices for medical products (17 June 2020) (accessed 18 October 2026)
- World Health Organization: Substandard and falsified medical products (fact sheet) (accessed 18 October 2026)
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines (accessed 18 October 2026)
- UAE Government portal (u.ae): Data protection laws, Federal Decree-Law No. 45 of 2021 on the Protection of Personal Data (accessed 18 October 2026)
- Saudi Data and AI Authority (SDAIA): National Data Governance Platform, Personal Data Protection Law (accessed 18 October 2026)
Related
- Licensing in the supply chain
- Privacy notice
- Questions to ask before you start
- Checklist for patients and families
- Reserve Meds vs Everyone.org: which fits a Gulf family?
- Answers to common access questions
- اقرأ هذه الصفحة بالعربية
This page is general information, not medical or legal advice. It does not replace advice from your own doctor or the regulator.